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Limited data exist on up-front autologous stem cell transplantation (ASCT) in extranodal natural killer/T cell
lymphoma (ENKTL). Sixty-two patients (43 men and 19 women) with newly diagnosed ENKTL who under-
went up-front ASCT after primary therapy were identiﬁed. Poor-risk characteristics included advanced stage
(50%), high-intermediate to high-risk International Prognostic Index (25.8%), and group 3 to 4 of NK/T Cell
Lymphoma Prognostic Index (NKPI, 67.7%). Pretransplant responses included complete remission in 61.3% and
partial remission in 38.7% of patients, and ﬁnal post-transplantation response included complete remission in
78.3%. Early progression occurred in 12.9%. At a median follow-up of 43.3 months (range, 3.7 to 114.6), 3-year
progression-free survival (PFS) was 52.4% and 3-year overall survival (OS) was 60.0%. Patients with limited
disease had signiﬁcantly better 3-year PFS (64.5% versus 40.1%, P ¼ .017) and OS (67.6% versus 52.3%, P ¼ .048)
than those with advanced disease. Multivariate analysis showed NKPI and pretransplant response were in-
dependent prognostic factors inﬂuencing survival, particularly NKPI in limited disease and pretransplant
response in advanced disease. Radiotherapy was an independent factor for reduced progression and survival
in patients with limited disease, but anthracycline-based chemotherapy was a poor prognostic factor for
progression in patients with advanced disease. Up-front ASCT is an active treatment in ENKTL patients
responding to primary therapy.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION involves nasal, paranasal, and oropharyngeal areas and is
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ty for Blood and Marrow Transplantation.closely associated with Epstein-Barr virus (EBV) infection
[1,2]. ENKTL is aggressive in nature and is frequently resistant
to anthracycline-based chemotherapy [3]. Although ENKTL is
more prevalent in East Asia than in Western countries, this
disease is generally rareworldwide [4]. Becauseof the rarityof
the disease and the consequent lack of prospective random-
ized trials, evidence-based standard therapy for ENKTL has
not been established. Given the fact that ENKTL is radiosen-
sitive disease [5,6], treatment strategies are mainly affected
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[stage I or II] or advanced [stage III or IV] disease). Several
more recent phase II studies in patients with limited disease
suggested that combined chemotherapyeradiotherapy was
associated with improvement of clinical outcomes [7-11]. In
addition, a small phase II study in patients with advanced
disease showed that a regimen of dexamethasone, metho-
trexate, ifosfamide, L-asparaginase, and etoposide (SMILE)
had a promising response rate and improved survival [12].
However, a substantial number of patients with ENKTL,
especially those with advanced disease, eventually experi-
ence relapse after treatments. Moreover, once ENKTL recurs,
prognosis is extremely dismal [13]. This suggests that further
treatment strategies are needed to prevent relapse and
improve the survival.
High-dose therapy with autologous stem cell trans-
plantation (ASCT) can be an attractive option for the treat-
ment of ENKTL as an up-front consolidation strategy [1].
However, the effectiveness of ASCT on patients with distinct
risk factors, optimal transplant timing, and available prog-
nostic parameters to predict better outcomes has not yet
been determined in ENKTL. Most data regarding ASCT in
ENKTL were derived from small case series, and interpreta-
tion was complicated by heterogeneous populations [14-19].
In fact, these studies included fewer than 20 cases with up-
front ASCT, and results from these studies are therefore not
readily applicable in up-front ASCT in ENKTL. It is likely that
prospective trials are ﬁnally needed to examine the role of
ASCT in the treatment of ENKTL. However, before treatment
strategies for up-front ASCT in ENKTL can be evaluated
prospectively, comprehensive analyses from retrospective
data may provide valuable insight into feasibility, response
and survival rates, clinical prognostic factors, and treatment
failure patterns for up-front ASCT strategies. Therefore, the
purpose of this study was to investigate clinical outcomes
and available prognostic factors in patients with ENKTL
treated by up-front ASCT after primary therapy. These ana-
lyses may provide basic data for designing future prospective
trials.METHODS
Patient Population and Diagnostic Evaluation
Patients were recruited from 9 institutions belonging to the Consortium
for Improving Survival of Lymphoma of the Korean Society of Hematology
LymphomaWorking Party. Patients were eligible for inclusion in the study if
they had received a diagnosis of ENKTL and underwent up-front ASCT after
primary therapy between January 2004 and December 2013. Diagnoses of
all patients included in this analysis were pathologically conﬁrmed by tumor
tissues obtained from the site of the disease, which were based on typical
histologic features: positive immunohistochemical expression of cyto-
plasmic CD3, CD56, and cytotoxic molecules and positive EBV in situ hy-
bridization results [20]. Patients were excluded if they had been diagnosed
with aggressive NK cell leukemia. Patients who underwent salvage ASCT
after disease progression were also excluded.
In all patients complete staging procedures, including medical history,
physical examination, complete blood count, serum biochemistry with
lactate dehydrogenase, computed tomography (CT) scan or magnetic reso-
nance imaging scan of the involved region, CT scan of chest and abdomen,
and bilateral bone marrow trephination biopsies, were performed. Baseline
positron emission tomography (PET)-CT scan was performed at the discre-
tion of the physicians based on their institution’s policy. Using the results of
these staging procedures, patients were classiﬁed into 2 groups: limited
disease and advanced disease groups. The limited disease group included
patients with stage I or II disease and the advanced disease group included
patients with stage III or IV disease. Prognosis was determined according to
the International Prognostic Index and the NK/T Cell Lymphoma Prognostic
Index (NKPI) [21].
Based on the site of primary tumor, ENKTL cases were divided into 2
groups: the upper aerodigestive tract NK/T cell lymphoma (UNKTL) and
extra-upper aerodigestive tract NK/T cell lymphoma (EUNKTL) groups [22].In brief, UNKTL was deﬁned as that involving the nasal cavity, nasopharynx,
and upper aerodigestive tract, whereas EUNKTL was deﬁned as the presence
of primary tumors at other regions in the absence of nasal disease. All pa-
tients provided written informed consent in accordance with institutional
guidelines, and the study protocol was reviewed and approved by the
institutional review board at each participating institution.Initial Treatment and Response Evaluation
Initial primary therapy consisted of the following treatment modalities:
anthracycline-based primary chemotherapy with or without involved-ﬁeld
radiotherapy (IFRT), noneanthracycline-based chemotherapy with or
without IFRT, and concurrent chemoradiotherapy with cisplatin followed by
noneanthracycline-based chemotherapy. The anthracycline-based chemo-
therapeutic regimens used were cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) and cyclophosphamide, doxorubicin,
vincristine, etoposide, and prednisone. Noneanthracycline-based chemo-
therapeutic regimens included SMILE; etoposide, ifosfamide, dexametha-
sone, and L-asparaginase (VIDL); ifosfamide, methotrexate, etoposide,
prednisone plus L-asparaginase (IMEP plus L-asp); and etoposide, ifosfa-
mide, cisplatin, and dexamethasone (VIPD). In patients with limited disease,
IFRT was administered after the completion of chemotherapy at the
discretion of the treating physician. Concurrent chemoradiotherapy con-
sisted of radiation therapy with a total dose of 36 to 44 Gy in 18 to 22
fractions and weekly administration of 30 mg/m2 cisplatin for 4 weeks.
According to primary chemotherapy, patients were categorized into 2
groups: anthracycline-based chemotherapy and noneanthracycline-based
chemotherapy groups (regardless of the sequence of chemotherapy and
[chemo]radiotherapy). Patients generally proceeded to ASCT when they
completed preplanned cycles of chemotherapy and achieved objective
response. However, patients could proceed to ASCT if they had signiﬁcant
regimen-related toxicities or reasons other than disease progression to
discontinue chemotherapy, which was at the discretion of the physician.
Tumor responses were assessed using the revised InternationalWorking
Group criteria [23]. If PET-CT was performed, the response of PET-CT was
assessed according to rules proposed by the International Harmonization
Project in lymphoma [24]. Pretransplant response was assessed within 4
weeks before conditioning chemotherapy was administered, and response
to ASCT was assessed 2 to 3 months after transplantation.Stem Cell Mobilization and High-Dose Therapy with ASCT Procedure
Stem cell mobilization for ASCT was performed according to published
recommendations [25]. Conditioning chemotherapy consisted of total body
irradiation (TBI)ebased and noneTBI-based regimens. The TBI-based
regimen was etoposide, cyclophosphamide, and fractionated TBI [19],
whereas noneTBI-based regimens included busulfan, cyclophosphamide,
and etoposide; busulfan, melphalan, and etoposide; busulfan, etoposide,
cytarabine, and melphalan; carmustine, etoposide, cytarabine, and
melphalan; and busulfan and thiotepa.Statistical Analysis
The primary endpoints were progression-free survival (PFS) and overall
survival (OS) after ASCT. Survival endpoints were calculated from the date of
ASCT until progression, death, or last follow-up, as appropriate. PFS and OS
were estimated using the Kaplan-Meier method. Clinical variables were
compared using Pearson’s chi-square test or Fisher’s exact test for categor-
ical variables and the Mann-Whitney test for continuous variables. Differ-
ences in PFS and OS among comparison groups were tested using a log-rank
test in univariate analyses. Multivariate analysis was carried out using Cox
proportional hazards models. Variables with P < .10 in univariate analyses
were included in the multivariate model. The results were reported with a
hazard ratio (HR) and 95% conﬁdence interval (CI). P< .05 was considered to
reﬂect statistical signiﬁcance. All statistical analyses were performed using
SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL).RESULTS
Patient Cohort
From 2004 to 2013, 66 patients with ENKTL who under-
went up-front ASCT were recruited. Of these 66 patients, 4
did not meet the entry criteria: 2 patients were initially
diagnosed with aggressive NK cell leukemia and 2 patients
underwent ASCT after salvage chemotherapy. In total, 62
patients were registered for this analysis.
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The pretransplant clinical characteristics of the 62
patients are summarized in Table 1. The median age was 45.5
years (range, 18 to 64), and the male-to-female ratio was
2.26:1. Most patients had Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1 (n ¼ 55, 88.7%)
and mainly presented as UNKTL (n ¼ 50, 80.6%). Primary
lesion locations of EUNKTL (n ¼ 12, 19.4%) included the
gastrointestinal tract (n ¼ 4), soft tissue (n ¼ 3), liver (n ¼ 2),
skin (n¼ 2), and testis (n¼ 1). More than 80% of patients (n¼
51, 82.3%) were initially treated with noneanthracycline-
based chemotherapy, including SMILE, VIDL, IMEP plus L-asp,
and VIPD. Based on the Ann Arbor stage, 31 patients (50%)
were categorized as belonging to the limited disease group
and 31 patients (50%) as belonging to the advanced disease
group. The number of extranodal organs involved was
signiﬁcantly greater in the advanced disease group (P< .001),
and the number of patients with EUNKTL was greater in the
advanced disease group, although this was of marginal sig-
niﬁcance (P ¼ .054). Thus, the advanced disease group had
more patients with higher risk International Prognostic In-
dex and NKPI scores than did the limited disease group. In
terms of treatment, more patients in the advanced disease
were initially treated with noneanthracycline-basedTable 1
Pretransplant Clinical Characteristics of Patients with ENKTL
Total (n ¼ 62) Limited Dis
Age, yr
Median 45.5 46.0
Range 18-64 34-64
Sex
Male 43 (69.4%) 20 (64.5%)
Female 19 (30.6%) 11 (35.5%)
ECOG performance status
0-1 55 (88.7%) 30 (96.8%)
2-4 7 (11.3%) 1 (3.2%)
B symptoms
Absent 40 (64.5%) 22 (71.0%)
Present 22 (35.5%) 9 (29.0%)
LDH
Normal 34 (54.8%) 19 (61.3%)
Elevated 28 (45.2%) 12 (38.7%)
Anatomic subtypes
UNKTL 50 (80.6%) 28 (90.3%)
EUNKTL 12 (19.4%) 3 (9.7%)
Extranodal organ involved
Median 1 1
Range 1-5 1
IPI
Low to LI 46 (74.2%) 31 (100.0%)
HI to high 16 (25.8%) 0 (0%)
NKPI
Low (groups 1-2) 20 (32.3%) 20 (64.5%)
High (groups 3-4) 42 (67.7%) 11 (35.5%)
Primary chemotherapy
Anthracycline-based 11 (17.7%) 8 (25.8%)
CHOEP 9 6
CHOP 2 2
Noneanthracycline-based 51 (82.3%) 23 (74.2%)
SMILE 23 1
VIDL 14 11
IMEP plus L-asp 10 8
VIPD 4 3
IFRT  chemotherapy
No 35 (56.5%) 7 (22.6%)
Yes 27 (43.5%) 24 (77.4%)
Pretransplant response
CR 38 (61.3%) 22 (71.0%)
PR 24 (38.7%) 9 (29.0%)
LDH indicates lactate dehydrogenase; IPI, International Prognostic Index; LI, low-in
vincristine, etoposide, prednisone.chemotherapy, although this difference was marginally sig-
niﬁcant (P ¼ .096, Table 1). Twenty-three of 31 patients
(74.2%) in the limited disease group had received radio-
therapy before they were offered ASCT. Other characteristics
did not differ signiﬁcantly between the 2 groups.
Clinical parameters associated with transplantation pro-
cedures are listed in Table 2. Although most patients (n ¼ 54,
87.1%) received noneTBI-based conditioning regimens, the
number of patients who received TBI-based conditioning
therapy was signiﬁcantly higher in the advanced disease
group (8 of 31, 25.8%; P ¼ .005). The median time from
diagnosis to transplant was signiﬁcantly shorter in the
advanced disease group (P < .001), which was associated
with both higher median cycles of systemic chemotherapy
and integration of radiotherapy in patients with limited
disease. Only 1 patient (1.6%) experienced transplant-related
mortality due to severe sepsis.
Treatment Outcomes and Therapy after Relapse
For the whole cohort, pretransplant responses consisted
of a complete remission (CR) in 38 patients (61.3%) and a
partial remission (PR) in 24 patients (38.7%). Final post-
transplant responses were evaluated in 60 of 62 patients
(96.7%). Of these patients, 47 (78.3%) achieved CR and 5ease (n ¼ 31) Advanced Disease (n ¼ 31) P
.587
45.0
18-63
.409
23 (74.2%)
8 (25.8%)
.104
25 (80.6%)
6 (19.4%)
.288
18 (58.1%)
13 (41.9%)
.307
15 (48.4%)
16 (51.6%)
.054
22 (71.0%)
9 (29.0%)
<.001
2
1-5
<.001
15 (48.4%)
16 (51.6%)
<.001
0 (0%)
31 (100.0%)
.096
3 (9.7%)
3
0
28 (90.3%)
22
3
2
1
<.001
28 (90.3%)
3 (9.7%)
.118
16 (51.6%)
15 (48.4%)
termediate; HI, high-intermediate; CHOEP, cyclophosphamide, doxorubicin,
Table 2
Clinical Parameters Associated with ASCT Procedures
Total (n ¼ 62) Limited Disease (n ¼ 31) Advanced Disease (n ¼ 31) P
Mobilization .307
G-CSF alone 28 (45.2%) 16 (51.6%) 12 (38.7%)
Chemotherapy plus G-CSF 34 (54.8%) 15 (48.4%) 19 (61.3%)
Cyclophosphamide 15 1 15
SMILE 16 11 4
DHAP 2 2 0
VIPD 1 1 0
Infused CD34þ cells (106/kg) .221
Median 7.02 6.78 7.80
Range 1.69-36.19 1.69-22.10 2.01-36.19
Conditioning therapy .005
TBI-based 8 (12.9%) 0 (0%) 8 (25.8%)
VCT 8 0 8
NoneTBI-based 54 (87.1%) 31 (100%) 23 (74.2%)
BuCyE or BuMelE 39 22 17
BuEAM 10 4 6
BEAM 3 3 0
BuT 2 2 0
Transplant-related mortality 1 (1.6%) 0 (0%) 1 (3.2%)
No. of chemotherapy received .064
Median 4 4 3
Range 3-8 3-8 3-8
Time from diagnosis to ASCT, mo <.001
Median 6.6 7.2 4.7
Range 3.0-10.3 4.1-10.3 3.0-10.0
G-CSF indicates granulocyte colony-stimulating factor; DHAP, dexamethasone, cytarabine, cisplatin; VCT, etoposide, cyclophosphamide, TBI; BuCyE, busulfan,
cyclophosphamide, etoposide; BuMelE, busulfan, melphalan, etoposide; BuEAM, busulfan, etoposide, cytarabine, melphalan; BEAM, camustine, etoposide,
cytarabine, melphalan; BuT, busulfan, thiotepa.
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within 3 months after transplantation (Table 3). Seven of 9
patients with pretransplant PR in the limited disease group
upgraded to CR after transplantation, but only 6 of 13 pa-
tients with pretransplant PR in the advanced disease group
achieved post-transplant CR. Thus, the number of patients
achieving post-transplant CR was signiﬁcantly higher in the
limited disease group (28 of 31, 90.3%) than the advanced
disease group (19 of 29, 65.5%; P ¼ .020; Table 3). With a
median follow-up of 43.3 months (range, 3.7 to 114.6), 30
patients (48.4%) had progressed, whereas 35 patients (56.5%)
were alive. The 3-year PFS rate was 52.4% (95% CI, 39.9% to
64.9%), and the 3-year OS rate was 60.0% (95% CI, 47.5% to
72.5%). In the limited disease group, the 3-year PFS and OS
rates were 64.5% (95% CI, 47.6% to 81.4%) and 67.6% (95% CI,
51.1% to 84.1%), respectively, and in the advanced disease
group the 3-year PFS and OS rates were 40.1% (95% CI, 22.3%
to 57.9%) and 52.3% (95% CI, 34.1% to 70.5%), respectively.
Both PFS and OS rates of the limited disease group were
signiﬁcantly better than those in the advanced disease group
(PFS, P ¼ .017; OS, P ¼ .048; Figure 1A, B).
Among the 30 patients who progressed after ASCT, 18
patients (60%) received salvage chemotherapies, whichTable 3
Post-Transplant Responses According to Pretransplant Responses
Post-Transplant Response
Limited Disease (n ¼ 31)
CR PR PD Su
Pretransplant response
CR 21 (95.5%) d 1 (4.5%) 22
PR 7 (77.8%) 1 (11.1%) 1 (11.1%) 9
Total 28 (90.3%) 1 (3.2%) 2 (6.5%) 31
PD indicates progressive disease.
* Post-transplant response status was not available in 2 patients with pretransp
evidence of disease progression at 1.4 and 2.0 months after transplantation, respeconsisted of L-asparaginaseecontaining regimens (n ¼ 11),
including SMILE (n ¼ 8); platinum-containing regimens (n ¼
6), including dexamethasone, cytarabine, cisplatin (n ¼ 3)
and ifosfamide, carboplatin, and etoposide (n ¼ 3); and
alemtuzumab with CHOP (n ¼ 1). Of those who had under-
gone salvage chemotherapy, only 5 patients (16.7%) achieved
objective responses (3 CR, 2 PR), and 2 patients (6.7%) un-
derwent allogeneic SCT while on remission.
Prognostic Factors for PFS and OS
Univariate and multivariate analyses to identify the
prognostic factors for PFS and OS were performed separately
in 2 steps. In the ﬁrst step, the analysis included all patients
(n ¼ 62). Age, sex, ECOG performance status, serum lactate
dehydrogenase level, Ann Arbor stage, B symptoms, pre-
transplant response, International Prognostic Index, NKPI,
anatomic subtypes, and primary chemotherapy were
included as independent variables for the analyses. In the
univariate analysis for PFS and OS, advanced stage was
associated with earlier progression (P ¼ .017) and death (P ¼
.048, Table 4). However, in the multivariate analysis,
advanced stage was not predictive of increased risk of pro-
gression and death. On the other hand, pretransplant PRP
Advanced Disease (n ¼ 29*)
m CR PR PD Sum
13 (81.3%) d 3 (18.8%) 16
6 (46.2%) 4 (30.8%) 3 (23.1%) 13
19 (65.5%) 4 (13.8%) 6 (20.7%) 29 .020
lant PR in the advanced disease group, because of early death without the
ctively.
Figure 1. Survival outcomes according to Ann Arbor stage. The limited disease
group had signiﬁcantly longer (A) PFS and (B) OS rates than the advanced
disease group.
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to 8.98]) and high-risk NKPI (PFS: HR, 2.85 [95% CI, 1.09 to
7.49]; OS: HR, 2.60 [95% CI, 1.19 to 5.66]) were independent
prognostic factors for shorter PFS and OS (Table 5, All pa-
tients). Poor ECOG performance status was also associatedTable 4
Univariate Analysis for PFS and OS
Variables No. of Patients 3-Year PFS
Age at diagnosis, yr
<60 55 48.5 (35.2-
60 7 85.7 (59.9-
Sex
Male 43 48.2 (33.1-
Female 19 62.7 (40.7-
Ann Arbor stage
Limited 31 64.5 (47.6-
Advanced 31 40.1 (22.3-
B symptoms
Absent 40 53.9 (38.2-
Present 22 50.0 (29.0-
ECOG performance status
0-1 55 55.4 (42.1-
2-4 7 28.6 (0-62
LDH
Normal 34 58.0 (41.1-
Elevated 28 45.7 (27.1-
Pretransplant response
CR 38 73.1 (58.8-
PR 24 20.8 (4.5-3
IPI
Low to LI 46 55.9 (41.4-
HI to high 16 42.2 (17.3-
NKPI
Low risk (groups 1-2) 20 75.0 (56.0-
High risk (groups 3-4) 42 41.5 (26.2-
Anatomic subtypes
UNKTL 50 55.5 (41.6-
EUNKTL 12 38.9 (10.1-
Primary chemotherapy
Noneanthracycline-based 51 49.8 (35.9-
Anthracycline-based 11 54.5 (25.1-
Values are percents, with 95% CIs in parentheses.with lower PFS (HR, 4.31 [95% CI, 1.48 to 12.60]) but was not
predictive of reduced OS (Table 5, All patients).
In the second step, statistical analyses were performed
separately based on Ann Arbor stages. In the limited disease
group (n ¼ 31), IFRT to the primary lesion was additionally
included as an independent variable for this analysis. In the
limited disease group, NKPI (P ¼ .025) and IFRT to the pri-
mary lesion (P ¼ .009) were signiﬁcantly associated with PFS
in the univariate analysis (Figure 2A,B). Moreover, anatomic
subtypes (P ¼ .014) were also signiﬁcantly related to pro-
gression. Based on the multivariate model, high-risk NKPI
(HR, 3.92 [95% CI, 1.05 to 14.67]) and EUNKTL (HR, 11.60 [95%
CI, 2.29 to 58.83]) were independent prognostic factors for
increased risk of progression, whereas IFRT to the primary
lesion (HR, .24 [95% CI, .06 to .92]) was independently asso-
ciated with a lower risk of progression (Table 5, Limited
disease patients). With other variables, such as serum lactate
dehydrogenase level and pretransplant response, the statis-
tical signiﬁcance in the univariate analysis disappeared after
the multivariate analysis. In the multivariate analysis for OS,
only IFRT to the primary lesion was associated with a
reduced risk of death (Table 5, Limited disease patients).
In the advanced disease group (n ¼ 31), conditioning
regimen was included as a variable for the analysis. In the
advanced disease group, pretransplant response (P ¼ .009)
and primary chemotherapy (P < .001) were signiﬁcantly
associated with PFS in the univariate analysis (Figure 2C, D).
In the multivariate analysis for PFS, pretransplant PR (HR,
3.09 [95% CI, 1.06 to 9.05]) and anthracycline-based primary
chemotherapy (HR, 10.44 [95% CI, 2.02 to 53.96]) were in-
dependent prognostic factors for reduced PFS (Table 5,P 3-Year OS P
.513 .473
61.8) 57.1 (43.8-70.4)
10.0) 85.7 (59.8-100.0)
.532 .453
63.3) 56.9 (41.8-72.0)
84.7) 67.4 (45.8-89.0)
.017 .048
81.4) 67.6 (51.1-84.1)
57.9) 52.3 (34.1-70.5)
1.0 .889
69.6) 61.3 (45.8-76.8)
71.0) 58.2 (37.2-79.2)
.006 .117
68.7) 62.1 (49.0-75.2)
.1) 42.9 (6.2-79.6)
.221 .413
74.9) 66.2 (49.7-82.7)
64.3) 52.6 (33.8-71.4)
<.001 .004
87.4) 72.4 (57.7-87.1)
7.1) 40.9 (20.9-60.9)
.121 .280
70.4) 64.3 (50.2-78.4)
67.1) 48.1 (23.0-73.2)
.004 .008
94.0) 80.0 (62.6-97.4)
56.8) 50.5 (35.0-66.0)
.282 .377
69.4) 63.1 (49.6-76.6)
67.7) 46.9 (17.5-76.3)
.383 .882
63.7) 59.0 (45.1-72.9)
83.9) 54.5 (25.1-83.9)
Table 5
Multivariate Analyses to Identify Prognostic Factors for PFS and OS
Variables HR 95% CI P
PFS
All patients (n ¼ 62)
NKPI
Low risk (groups 1-2) 1
High risk (groups 3-4) 2.85 1.09-7.49 .033
Pretransplant response
CR 1
PR 4.12 1.90-8.91 <.001
ECOG performance status
0-1 1
2-4 4.31 1.48-12.60 .008
Limited disease patients (n ¼ 31)
NKPI
Low risk (groups 1-2) 1
High risk (groups 3-4) 3.92 1.05-14.67 .043
Anatomic subtypes
UNKTL 1
EUNKTL 11.60 2.29-58.83 .003
IFRT to primary lesion
No 1
Yes .24 .06-.92 .038
Advanced disease patients (n ¼ 31)
Pretransplant response
CR 1
PR 3.09 1.06-9.05 .039
Primary chemotherapy
Noneanthracycline-based 1
Anthracycline-based 10.44 2.02-53.96 .005
OS
All patients (n ¼ 62)
NKPI
Low risk (groups 1-2) 1
High risk (groups 3-4) 3.22 1.15-8.98 .026
Pretransplant response
CR 1
PR 2.60 1.19-5.66 .016
Limited disease patients (n ¼ 31)
IFRT to primary lesion
No 1
Yes .24 .07-.80 .021
Advanced disease patients (n ¼ 31)
Primary chemotherapy
Noneanthracycline-based 1
Anthracycline-based 51.58 5.40-493.07 .001
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.004) was signiﬁcantly associated with progression in the
univariate analysis but was not an independent predictive
factor for PFS in the multivariate model. In the multivariate
analysis for OS, anthracycline-based primary chemotherapy
was the only independent factor for increased risk of death
(Table 5, Advanced disease patients).DISCUSSION
This study is the ﬁrst to investigate clinical outcomes of
up-front ASCT with a large patient cohort, considering the
rarity of ENKTL. Because the data were collected retrospec-
tively and ASCT itself is inﬂuenced by age and/or comor-
bidity, a degree of patient selection would be present in this
study. However, it is noteworthy that up-front ASCT in ENKTL
has been generally considered for patients responding to
initial therapy, whereas it is rarely offered to patients who
are unresponsive to primary therapy. Considering that about
15% to 30% of patients with B or T cell lymphoma initially
considered for up-front ASCT could not proceed to trans-
plantation due mainly to disease progression [26,27], our
study might represent the group of patients who are
transplant-eligible after primary therapy. Additionally,compared with previously published series of ENKTL
[21,28,29], the cohort in this study was concordant with
typical features and characteristics of ENKTL patients (male
dominant by 2.26-fold, median age 45.5 years, and primary
lesions predominantly around the nasal cavity [80.4%]).
Therefore, these ﬁndings suggest that our cohort might be
considered as representative of typical ENKTL cases
responding to initial primary therapy.
In this present analysis, we demonstrated that ASCT is a
feasible and effective therapy in ENKTL patients who
respond to initial primary therapy. In the limited disease
group, clinical outcomes after transplantation were strongly
associated with NKPI at diagnosis and IFRT to the primary
lesion. This ﬁnding may imply that patients with a low-risk
NKPI had excellent outcomes compared with those with a
high-risk NKPI. However, given the excellent outcomes in
several phase II studies regarding treatment strategies using
noneanthracycline-based chemotherapy and (chemo)
radiotherapy in patients with limited-stage ENKTL (PFS, 60%
to 86% at 2 to 3 years; OS, 73% to 88% at 2 to 3 years), the
survival outcomes of our study were similar to those of
previous prospective studies [7-11]. Although more patients
with limited disease had a high-risk NKPI in this study
compared with previous studies (36% versus 20% to 30%) [7-
10], these ﬁndings suggest that up-front ASCT should not be
performed uniformly in all patients with limited disease but
may be considered in highly selected cases. In this sense, it
is important to consider parameters that may predict which
patients would receive the most beneﬁt from up-front ASCT
strategies. Using a matched control method, Lee et al. [14]
investigated the impact of ASCT on clinical outcomes in 47
ENKTL patients, including 31 cases of stage I/II disease, and
demonstrated that survival was not different between the
transplant group and matched control group. However, in
the subgroup analysis, ASCT conferred a survival beneﬁt in
patients who attained CR and had a high-risk NKPI [14].
Furthermore, Kim et al. [30] recently reported that com-
bined analyses of both circulating EBV DNA and PET-CT
response could predict recurrence of ENKTL in patients
treated with concurrent chemoradiotherapy or non-
eanthracycline-based chemotherapy. In this report, they
showed that approximately 60% of patients with EBV DNA
positivity or Deauville score 3 to 4 of PET-CT results after the
completion of chemotherapy would have recurrence, which
was signiﬁcantly higher than those with both negative EBV
DNA and Deauville score 1 to 2 of PET-CT. Thus, application
of ASCT in limited-stage ENKTL should be tailored to pa-
tients most likely to beneﬁt from this approach. In future
studies, risk-, biomarker-, and response-adapted treatment
strategies using NKPI [14], EBV DNA [30-32], and PET-CT
ﬁndings [30] need to be investigated in this group of
patients.
Interestingly, omitting radiotherapy in limited disease
was aworse prognostic factor for PFS and OS, whichmight be
related to frequent failure around the primary lesion. This
ﬁnding was consistent with previous studies regarding the
therapeutic role of radiotherapy [6,20,33]. Based on reports,
disease progression during chemotherapy occurred in 30% to
40% of patients, requiring salvage radiotherapy [6,20]. These
ﬁndings may implicate that chemotherapy, even high-dose
therapy, does not satisfactorily prevent local failure.
Conversely, radiotherapy should be an integral part of
treatment, even if followed by ASCT. Therefore, our data
highlight the importance of radiotherapy for the treatment of
limited-stage ENKTL.
Figure 2. PFS in the (A and B) limited disease group and (C and D) advanced disease group. Comparison according to the (A) NKPI and (B) radiotherapy to the primary
lesion in the limited disease group showed that a low-risk NKPI and combined chemotherapyeradiotherapy were associated with signiﬁcantly longer PFS rates than a
high-risk NKPI and chemotherapy alone, respectively. When we compared PFS in patients with advanced disease according to (C) pretransplant response and (D)
primary chemotherapy, pretransplant CR achievement and noneanthracycline-based primary chemotherapy were associated with signiﬁcantly better PFS than
pretransplant PR and anthracycline-based chemotherapy, respectively.
H.-Y. Yhim et al. / Biol Blood Marrow Transplant 21 (2015) 1597e1604 1603In the present analysis, advanced disease was not an in-
dependent factor for increased risk of progression or death.
This may be associated with better than expected outcomes
of patients with advanced disease. Current non-
eanthracycline-based chemotherapy might induce
improved disease control before ASCT, which translated into
survival outcomes after transplantation, especially in pa-
tients with pretransplant CR. Indeed, the survival outcomes
(3-year PFS, 40%; 3-year OS, 52%) of patients with advanced-
stage ENKTL were quite beyond expectations. Additionally,
multivariate analysis showed that pretransplant PR and
anthracycline-based chemotherapy were important pre-
dictors for disease progression. The prognostic signiﬁcance of
pretransplant disease status has already been suggested in
several retrospective studies investigating ASCT in ENKTL
[14,15]. These ﬁndings suggest that patients achieving CR
with primary therapy might be most likely to beneﬁt from
up-front ASCT strategies. Therefore, advanced-stage ENKTL
patients achieving CR after noneanthracycline-based
chemotherapy need to be considered for up-front ASCT. On
the other hand, in the present study, the outcomes of pa-
tients in the advanced disease group achieving PR with pri-
mary therapy were dismal; a 13.3% 3-year PFS rate was
observed. Given the extremely poor outcomes of advanced-
stage patients with PR, up-front ASCT might not be a
feasible treatment strategy in the PR cohort. Thus, novel
treatment approaches are urgently needed to improve out-
comes for the PR cohort.
However, even if encouraging survival outcomes were
observed after up-front ASCT, approximately 20% of patients
with advanced disease progressed within 3 months after
transplantation. Current data have suggested that non-
eanthracycline-based chemotherapy, such as SMILE, may be
a mainstay of treatment in advanced-stage ENKTL [12,34]. Inour study, 90.3% of the patients with advanced disease
received noneanthracycline-based chemotherapy, mostly
the SMILE regimen. This ﬁnding indicates that further
effective treatment modalities are needed for advanced-
stage ENKTL. Thus, treatment intensiﬁcation of primary
chemotherapy or other novel treatment strategies needs to
be urgently investigated in this group of patients.
There are several limitations of our study. First, the cur-
rent analysis is based on retrospective data with a relatively
short follow-up duration. Additionally, the small number of
cases in the subgroup analyses may restrict the generaliz-
ability of our ﬁndings. This should always be considered
when interpreting the results; therefore, the data presented
here could be used as a historical reference before generating
a hypothesis for designing prospective trials. Second, the
results of circulating EBV DNA levels, recently identiﬁed as a
valuable biomarker of tumor load [30-32,35,36], was not
included in the current analysis, because measurement
timing, interval, frequency, and assay methods of EBV DNA
were different according to each participating institution’s
policy. Considering the prognostic role of circulating EBV
DNA levels in recently published series for ENKTL, it should
be measured in future prospective studies regarding ASCT in
ENKTL [30-32,35,36].
In conclusion, up-front ASCT may be a feasible and
active treatment option in patients with ENKTL who
respond to primary therapy. NKPI and pretransplant
response are important factors for predicting clinical out-
comes, particularly NKPI in limited disease and pretrans-
plant disease status in advanced disease. Additionally,
radiotherapy plays an essential role in the treatment of
limited-stage disease, even if ASCT is offered. Alternatively,
in the management of advanced disease, anthracycline-
based chemotherapy should be avoided because it is
H.-Y. Yhim et al. / Biol Blood Marrow Transplant 21 (2015) 1597e16041604associated with inferior outcomes, and patients who ach-
ieved CR after noneanthracycline-based chemotherapy
should be considered for studies evaluating up-front ASCT
strategies. To improve outcome in patients with advanced
disease, novel treatment strategies need to be further
explored. Finally, the present data provide reference points
for future studies regarding up-front ASCT in ENKTL.
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